ReviewPlant cell reports2012
The use of plants for the production of therapeutic human peptides.
Review in Plant cell reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Article
- Development of Virus-like Particle Plant-Based Vaccines against Avian H5 and H9 Influenza A Viruses.Veterinary sciences · 2024Article
- Article
- Efficient in planta production of amidated antimicrobial peptides that are active against drug-resistant ESKAPE pathogens.Nature communications · 2023Article
- Production of Plant Proteases and New Biotechnological Applications: An Updated Review.ChemistryOpen · 2022Review
- CRISPR/Cas9-mediated knockout of the DCL2 and DCL4 genes in Nicotiana benthamiana and its productivity of recombinant proteins.Plant cell reports · 2022Article
- Genetic Manipulation and Bioreactor Culture of Plants as a Tool for Industry and Its Applications.Molecules (Basel, Switzerland) · 2022Review
- Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines.Plants (Basel, Switzerland) · 2021Review
- Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice.Plant biotechnology journal · 2021Article
- Plant Molecular Farming as a Strategy Against COVID-19 - The Italian Perspective.Frontiers in plant science · 2020Article
- Purification of the recombinant green fluorescent protein from tobacco plants using alcohol/salt aqueous two-phase system and hydrophobic interaction chromatography.BMC biotechnology · 2019Article
- Article
- Rapid and Scalable Plant-Based Production of a Potent Plasmin Inhibitor Peptide.Frontiers in plant science · 2019Article
- Small, Smaller, Nano: New Applications for Potato Virus X in Nanotechnology.Frontiers in plant science · 2019Review
- Production of Bioactive Recombinant Reteplase by Virus-Based Transient Expression System inFrontiers in plant science · 2019Article
- Repurposing Plant Virus Nanoparticles.Vaccines · 2018Review
- Development ofFrontiers in chemistry · 2018Article
- Reconceptualizing cancer immunotherapy based on plant production systems.Future science OA · 2017Review
- Production of BP178, a derivative of the synthetic antibacterial peptide BP100, in the rice seed endosperm.BMC plant biology · 2017Article
- Recombinant Plant Engineering for Immunotherapeutic Production.Current molecular biology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptides have unique properties that make them useful drug candidates for diverse indications, including allergy, infectious disease and cancer. Some peptides are intrinsically bioactive, while others can be used to induce precise immune responses by defining a minimal immunogenic region. The limitations of peptides, such as metabolic instability, short half-life and low immunogenicity, can be addressed by strategies such as multimerization or fusion to carriers, to improve their pharmacological properties. The remaining major drawback is the cost of production using conventional chemical synthesis, which is also difficult to scale-up. Over the last 15 years, plants have been shown to produce bioactive and immunogenic peptides economically and with the potential for large-scale synthesis. The production of peptides in plants is usually achieved by the genetic fusion of the corresponding nucleotide sequence to that of a carrier protein, followed by stable nuclear or plastid transformation or transient expression using bacterial or viral vectors. Chimeric plant viruses or virus-like particles can also be used to display peptide antigens, allowing the production of polyvalent vaccine candidates. Here we review progress in the field of plant-derived peptides over the last 5 years, addressing new challenges for diverse pathologies.
Indexed as
Identifiers
22218674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.